Welcome to Seacross Pharmaceuticals Ltd.
Products
Oncology Injectable Other Product 1 Other Product 2
Pemetrexed Seacross 500 mg

Therapeutic indications: 

• Malignant pleural mesothelioma

In combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma.


• Non-small cell lung cancer

In combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Form Powder for concentrate for solution for infusio
Strength 100mg/vial, 500mg/vial
Active substance Pemetrexed
Other ingredients Mannitol, hydrochloric acid, sodium hydroxide
© Copyright - Clinico fusce blandit sapien eu